Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.

Blood advances - 23 Dec 2019

Neumeyer Joseph, Lin Ruei-Zeng, Wang Kai, Hong Xuechong, Hua Tien, Croteau Stacy E, Neufeld Ellis J, Melero-Martin Juan M

Abstract excerpt

Hemophilia A (HA) is a bleeding disorder caused by mutations in the F8 gene encoding coagulation factor VIII (FVIII). Current treatments are based on regular infusions of FVIII concentrates throughout a patient's life. Alternatively, viral gene therapies that directly deliver F8 in vivo have shown preliminary successes. However, hurdles remain, including lack of infection specificity and the inability to deliver...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation
Share to Blood Coagulation Tests

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Embryonic Stem Cells

Share to Factor VIII

Share to Gene Transfer Techniques

Share to Hemophilia A

Share to Microvessels

Share to Stem Cell Transplantation

Source

Open in PubMed Open full text

Identifiers

PMID: 31851760
DOI: 10.1182/bloodadvances.2019000848
PMCID: PMC6929393

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.PMID 31851760Read ↗

Endothelial cells derived from patients’ induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia ASemantic proximity Read ↗

Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia ASemantic proximity Read ↗

Long-term correction of hemophilia A via integration of a functionally enhanced FVIII gene into the AAVS1 locus by nickase in patient-derived iPSCsSemantic proximity Read ↗

Restoration of FVIII Function and Phenotypic Rescue in Hemophilia A Mice by Transplantation of MSCs Derived From F8-Modified iPSCsSemantic proximity Read ↗

ssODN-Mediated In-Frame Deletion with CRISPR/Cas9 Restores FVIII Function in Hemophilia A-Patient-Derived iPSCs and ECsSemantic proximity Read ↗

Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable deviceSemantic proximity Read ↗

Improved Intrvenous Lentiviral Gene Therapy Based on Endothelial-specific Factor VIII for Hemophilia ASemantic proximity Read ↗

Delivery of Full-Length Factor VIII Using a piggyBac Transposon Vector to Correct a Mouse Model of Hemophilia ASemantic proximity Read ↗

Therapeutic correction of hemophilia A using 2D endothelial cells and multicellular 3D organoids derived from CRISPR/Cas9-engineered patient iPSCsSemantic proximity Read ↗

Modeling of hemophilia A using patient-specific induced pluripotent stem cells derived from urine cells.Semantic proximity Read ↗

Phenotypic correction of murine hemophilia A using an iPS cell-based therapy.Semantic proximity Read ↗

Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.